**Name of Journal:** *World Journal of Cardiology*

**Manuscript NO:** 64073

**Manuscript Type:** ORIGINAL ARTICLE

***Retrospective Study***

**Patients’ time in therapeutic range on warfarin among atrial fibrillation patients in Warfarin Medication Therapy Adherence Clinic**

Lee SL *et al*. predictors of poor TTR

Siew Ling Lee, Thien Jian Ong, Wardati Mazlan-Kepli, Annuysia Mageswaran, Kai Hsin Tan, Abdul-Muizz Abd-Malek, Robert Cronshaw

**Siew Ling Lee, Thien Jian Ong, Wardati Mazlan-Kepli, Annuysia Mageswaran, Kai Hsin Tan,** Department of Pharmacy, Hospital Serdang, Ministry of Health Malaysia, Kajang 43000, Selangor, Malaysia

**Abdul-Muizz Abd-Malek,** Department of Cardiology, Hospital Serdang, Ministry of Health Malaysia, Kajang 43000, Selangor, Malaysia

**Robert Cronshaw,** College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow G128QQ, United Kingdom

**Author contributions:** Mazlan-Kepli W contributed to the idea and study design; Siew-Ling L, Thien-Jian O, and Annuysia M contributed to and performed all data analyses and interpretation of results; Siew-Ling L and Thien-Jian O wrote the first manuscript; Wardati MK contributed to the interpretation of results and critically reviewed the final manuscript; All authors contributed to the review of an approved manuscript before submission.

**Correspondence to: Siew Ling Lee, BPharm, Pharmacist,** Department of Pharmacy, Hospital Serdang, Ministry of Health Malaysia, Jalan Puchong, Kajang 43000, Selangor, Malaysia. siewling.phc@gmail.com

**Received:** March 10, 2021

**Revised:** May 25, 2021

**Accepted:** July 26, 2021

**Published online:**

**Abstract**

BACKGROUND

The quality of warfarin therapy can be determined by the time in the therapeutic range (TTR) of international normalized ratio (INR). The estimated minimum TTR needed to achieve a benefit from warfarin therapy is ≥ 60%.

AIM

To determine TTR and the predictors of poor TTR among atrial fibrillation patients who receive warfarin therapy.

METHODS

A retrospective observational study was conducted at a cardiology referral center in Selangor, Malaysia. A total of 420 patients with atrial fibrillation and under follow-up at the pharmacist led Warfarin Medication Therapeutic Adherence Clinic between January 2014 and December 2018 were included. Patients’ clinical data, information related to warfarin therapy, and INR readings were traced through electronic Hospital Information system. A data collection form was used for data collection. The percentage of days when INR was within range was calculated using the Rosendaal method. The poor INR control category was defined as a TTR < 60%. Predictors for poor TTR were further determined by using logistic regression.

RESULTS

A total of 420 patients [54.0% male; mean age 65.6 (10.9) years] were included. The calculated mean and median TTR were 60.5% ± 20.6% and 64% (interquartile range 48%-75%), respectively. Of the included patients, 57.6% (*n* = 242) were in the good control category and 42.4% (*n* = 178) were in the poor control category. The annual calculated mean TTR between the year 2014 and 2018 ranged from 59.7% and 67.3%. A high HAS-BLED score of ≥ 3 was associated with poor TTR (adjusted odds ratio, 2.525; 95% confidence interval: 1.6-3.9, *p* < 0.001).

CONCLUSION

In our population, a high HAS-BLED score was associated with poor TTR. This could provide an important insight when initiating an oral anticoagulant for these patients. Patients with a high HAS-BLED score may obtain less benefit from warfarin therapy and should be considered for other available oral anticoagulants for maximum benefit.

**Key Words:** Atrial fibrillation; Time in therapeutic range; International normalized ratio; HAS-BLED score; Oral anticoagulants; Warfarin Medication Therapeutic Adherence Clinic

Lee SL, Ong TJ, Mazlan-Kepli W, Mageswaran A, Tan KH, Abd-Malek AM, Cronshaw R. Patients’ time in therapeutic range on warfarin among atrial fibrillation patients in Warfarin Medication Therapy Adherence Clinic. *World J Cardiol* 2021; In press

**Core Tip:** This is a retrospective observational study to determine time in therapeutic range (TTR) and the predictors of poor TTR among patients with atrial fibrillation under follow-up at the Warfarin Medication Therapeutic Adherence Clinic of a tertiary cardiology referral center in Selangor, Malaysia. In this study cohort, we found that high HAS-BLED score (≥ 3) was a significant predictor of poor TTR.

**INTRODUCTION**

Atrial fibrillation (AF) is usually asymptomatic and is associated with an increased risk of major adverse cardiovascular events (MACE) and mortality in patients with coronary artery disease (CAD)[1]. The prevalence of AF in the Malaysian population is low at 0.54%, compared to the global average of 1%[2].

Warfarin is the most widely used anticoagulant in the world[3–5]. Although novel oral anticoagulants are available, warfarin remains a viable oral anticoagulant for many patients because of its availability and cost[4,6,7]. The time in therapeutic range (TTR) estimates the percentage of time a patient’s international normalized ratio (INR) is within the desired treatment range or goal and is widely used as an indicator of anticoagulation control[4,9–12]. TTR is commonly used to evaluate the quality of warfarin therapy and is an essential tool for assessing the risks *vs* benefits of warfarin therapy[4,8,13,14]. A 10% increase in time spent out of TTR is associated with a 29% increase in the risk of mortality and a 10%-12% increase in the risk of an ischemic stroke and other thromboembolic events[13,15–17].

The aim of this study is to determine the percentage of time a patient’s INR is within the desired treatment range and the predictors of poor TTR among patients with AF who receive warfarin therapy.

**MATERIALS AND METHODS**

***Study design***

This is a retrospective observational study that was conducted in Hospital Serdang located in Kajang, Selangor. Hospital Serdang is a cardiology reference center that covers patients from Serdang, Bangi, Putrajaya, Kajang, Dengkil, and Puchong area in the state of Selangor, Malaysia. Ethical approval for this study was obtained from the Medical Research and Ethics Committee, Ministry of Health Malaysia (NMRR-19-839-46462). The study was carried out in accordance with the Declaration of Helsinki.

***Study setting and study population***

All AF patients under Warfarin Medication Therapeutic Adherence Clinic follow-up between 2014 to 2018 were included. The electronic Hospital Information System (eHIS) was used to extract patients’ demographics, comorbidities, information related to warfarin therapy, and INR readings. Baseline comorbidities were retrospectively retrieved according to available medical records in eHIS. The consecutive sampling method was used. A case report form was used for data collection. Each patient was allocated a patient identifier number that matched their patient registration number, in order to protect confidentiality. Patients were excluded if they discontinued warfarin therapy, died, or had less than three INR readings.

***TTR***

For patients with AF, the target INR range was between 2.0 to 3.0. TTR is defined as an estimate of the average time that a medication is dosed with optimal efficacy and safety[4]. From previous literature, the estimate of the minimum TTR needed to achieve a benefit from warfarin therapy is between 58% and 65%[18]. The percentage of days that INR was within range was calculated using the Rosendaal method[8]. Thus, based on these references, we defined the “poor” TTR category as TTR < 60% and the “good” TTR category as TTR > 60%.

***Statistical analysis***

This study aimed to determine to what extent the following factors are associated with poor TTR: Age, gender, ethnicity, diabetes mellitus, hypertension, previous ischemic heart disease, chronic kidney disease, peripheral vascular disease, stroke/transient ischemic attack, deep vein thrombosis/pulmonary embolism, heart failure, chronic obstructive pulmonary disease/asthma, chronic kidney disease, dyslipidaemia, chronic rheumatic heart disease, CHA2DS2-VASc score, and HAS-BLED score. A study by Peduzzi *et al*[19] on sample size for logistic regression suggests using a minimum event per variable value of ten. Since our study was interested in studying 17 risk factors, a minimum sample of 170 patients in the poor TTR category group was required. The study planned to recruit at least 400 samples in order to exceed the minimum sample size, as the prevalence of poor TTR was estimated at 38%[19].

Categorical variables were summarized using frequencies and proportions while continuous variables were summarized using mean ± standard deviation or median (inter-quartile range) values. Logistic regression analysis was used to calculate odds ratios (OR) and 95% confidence intervals (CI) to model the predictors of poor TTR. This analysis was repeated and adjusted to variables that were significant from the previous studies: Heart failure, chronic kidney disease, CHA2DS2-VASc score, and HAS-BLED score[20]. A *p* < 0.05 was considered significant. Point estimates and 95%CI are presented for all results. Statistical analyses were performed using IBM SPSS Statistics for Windows, version 20 (Armonk, NY, United States).

**RESULTS**

A total of 420 patients with AF were included in this study (Figure 1). Baseline characteristics are shown in Table 1. The mean age of the study population was 65.7 (10.9) years. There were slightly more male patients (54%, *n* = 227) than female patients (46%, *n* = 193). The largest ethnic population was Malay, followed by Chinese and Indian. Hypertension accounted for the highest percentage of comorbidities among patients with AF, followed by diabetes mellitus, dyslipidaemia, and ischemic heart diseases. Median CHA2DS2-VASc score was 3 (moderate risk of stroke), and median HAS-BLED score was 2 (low bleeding risk).

***Time in therapeutic range***

Over 5 years, the mean (standard deviation) TTR was 60.6% (20.6%) with a median of 64% (interquartile range 27%). Of the included patients, 57.6% (*n* = 242) were in the good control category, and 42.4% (*n* = 178) were in the poor control category (Table 2). The annual calculated mean TTR between the year 2014 and 2018 ranged between 59.7% and 67.3%. The highest percentage was in 2018, with 67.3% of days within therapeutic range in AF patients. Figure 2 shows the mean TTR for AF patients from 2014 to 2018. Patient with a high HAS-BLED (score ≥ 3) had a median TTR of 55% compared to patients with a low HAS-BLED score, who had a median TTR of 68% (Figure 3).

***Predictors of poor TTR***

From the multivariate analysis, a high HAS-BLED score (score ≥ 3) was significantly associated with a poor TTR (< 60%) (adjusted OR, 2.5;1.6-3.9, *p* < 0.001) compared to a low HAS-BLED score (score ≤ 2). Similarly, in the model adjusted for predictors previously described in previous reports[20] (model 2), only HAS-BLED score was found to be a significant predictor of poor TTR (adjusted OR, 2.9;1.9-4.4, *p* < 0.001) (Table 3).

**DISCUSSION**

This study assessed the percentage of time a patient’s INR is within the desired treatment range or TTR and explored the predictors of poor TTR. Overall, the study population had a majority of men and people of Malay ethnicity. This could be explained by the Malaysian population distribution, whereby more than half of the population are of Malay ethnicity, and there are more men than women with the ratio of 107:100[21]. Our results showed similarity with other international studies, with a majority of warfarin users being male[22,23].

Hypertension had the highest prevalence, followed by diabetes mellitus, hyperlipidemia, and ischemic heart disease. The higher prevalence of cardiac-related comorbidities could be explained by Hospital Serdang’s status as a cardiology center, therefore catering towards patients with cardiovascular disease in the region. Additionally, these are the main risk factors for AF, which is the study population in question[24].

Interestingly, when compared to other Asian studies, the mean TTR of patients obtained in the study was 60.6%. In comparison, a study from Korea recorded a mean TTR of 49.1%[23], and a study from Singapore recorded a mean TTR of 58%[25]. Possible reasons for the higher mean TTR percentage may be due to the involvement of pharmacists in the pharmacist-led warfarin therapy. This translates to improved patient counselling, dosage adjustment, and identification of possible food-drug and drug-drug interactions.

This study found that patients with a high HAS-BLED score (≥ 3) had a lower median TTR of 55%, compared to patients with a low HAS-BLED score (score < 2) who had a higher median TTR of 68%. Previous reports have suggested that heart failure, chronic kidney disease, and CHA2DS2-VASc score in addition to high bleeding risk may also contribute to poor TTR[20]. After adjusting for these variables, we found only high HAS-BLED (score ≥ 3) was associated with poor TTR. This is supported by the study from Urbonas *et al*[15], which found median TTR was significantly lower in patients with high bleeding risk (36.4%) as compared to low-risk patients (55.6%). They suggested that the poor TTR in these patients may be due to biological variation in clotting factors[15].

***Strength and limitations***

Our patients’ data were derived from the eHIS database, an electronic storage system of patient records, enabling straightforward access to patient records. The INR results collected in the study were obtained either through point-of-care testing (POC) or clinical laboratory INR. There may be bias in INR measurements calculated using POC compared with laboratory INR, as POC measurements tend to be higher[10], which may affect subsequent INR readings. We were unable to measure objectively patient compliance to warfarin as a risk factor for poor TTR. Since it was a retrospective study, possible missed documentation may have occurred.

**CONCLUSION**

This study found the mean TTR was 60.5% in patients with AF and that a high HAS-BLED score (≥ 3) was associated with poor TTR. This could provide an important insight during the initiation of oral anticoagulant for patients with a high HAS-BLED score, who may obtain less benefit from warfarin therapy. They should therefore be considered for other available oral anticoagulants for maximum benefit.

**ARTICLE HIGHLIGHTS**

***Research background***

the time in therapeutic range (TTR) is a quality measure for anticoagulation therapy with warfarin.

***Research motivation***

TTR of international normalized ratio (INR) needs to be achieved with a percentage of ≥ 60% for patient to receive a maximal benefit from warfarin such as preventing stroke, major bleeding, and even death.

***Research objectives***

TTR and the predictors of poor TTR need to be evaluated among atrial fibrillation (AF) patients that received warfarin therapy.

***Research methods***

Eligible patients with AF from January 2014 to December 2018 for INR monitoring were included in this study. Demographic data, indication of warfarin therapy, INR target, and percentage of INR within range were collected using a data collection form. TTR was assessed using Rosendaal method.

***Research results***

In patients with AF, the mean TTR was 60.5% with the highest TTR score achieved in 2018, with a percentage of 67%.

***Research conclusions***

This study showed that high HAS-BLED score was associated to poor TTR.

***Research perspectives***

Patients with AF and high HAS-BLED score may have less benefit from warfarin therapy. Thus, other alternative oral anticoagulants should be considered for maximum benefit.

**ACKNOWLEDGEMENTS**

The authors would like to thank the Director-General of Health Malaysia for the permission to publish this paper and to those who contributed directly or indirectly in this study. Further on, the authors would also like to thank the colleagues Siaw SH, Tam AS, Mohamad RIA, Wong KY, Noor Hisham NA, So SH, Lim SY, Tee CY, and Tang MH for their contribution in data collection.

**REFERENCES**

1 **Vrsalović M**, Presečki AV. Atrial fibrillation and risk of cardiovascular events and mortality in patients with symptomatic peripheral artery disease: A meta-analysis of prospective studies. *Clin Cardiol* 2017; **40**: 1231-1235 [PMID: 29243858 DOI: 10.1002/clc.22813]

2 **Lim CW**, Kasim S, Ismail JR, Chua NY, Najme Khir R, Zainal Abidin HA, Abdul Rahman E, Mohd Arshad MK, Ibrahim Othman Z, Yusoff K. Prevalence of atrial fibrillation in the Malaysian communities. *Heart Asia* 2016; **8**: 62-66 [PMID: 27933105 DOI: 10.1136/heartasia-2016-010775]

3 **Pirmohamed M**. Warfarin: almost 60 years old and still causing problems. *Br J Clin Pharmacol* 2006; **62**: 509-511 [PMID: 17061959 DOI: 10.1111/j.1365-2125.2006.02806.x]

4 **Farsad BF**, Abbasinazari M, Dabagh A, Bakshandeh H. Evaluation of Time in Therapeutic Range (TTR) in Patients with Non-Valvular Atrial Fibrillation Receiving Treatment with Warfarin in Tehran, Iran: A Cross-Sectional Study. *J Clin Diagn Res* 2016; **10**: FC04-FC06 [PMID: 27790456 DOI: 10.7860/JCDR/2016/21955.8457]

5 **Mwita JC**, Francis JM, Oyekunle AA, Gaenamong M, Goepamang M, Magafu MGMD. Quality of Anticoagulation With Warfarin at a Tertiary Hospital in Botswana. *Clin Appl Thromb Hemost* 2018; **24**: 596-601 [PMID: 29258394 DOI: 10.1177/1076029617747413]

6 **You JH**. Novel oral anticoagulants *vs* warfarin therapy at various levels of anticoagulation control in atrial fibrillation--a cost-effectiveness analysis. *J Gen Intern Med* 2014; **29**: 438-446 [PMID: 24132628 DOI: 10.1007/s11606-013-2639-2]

7 **Shields LBE**, Fowler P, Siemens DM, Lorenz DJ, Wilson KC, Hester ST, Honaker JT. Standardized warfarin monitoring decreases adverse drug reactions. *BMC Fam Pract* 2019; **20**: 151 [PMID: 31699045 DOI: 10.1186/s12875-019-1041-5]

8 **Gateman D**, Trojnar ME, Agarwal G. Time in therapeutic range: Warfarin anticoagulation for atrial fibrillation in a community-based practice. *Can Fam Physician* 2017; **63**: e425-e431 [PMID: 29025819]

9 **Bahbahani H**, AlTurki A, Dawas A, Lipman ML. Warfarin anticoagulation in hemodialysis patients with atrial fibrillation: comparison of nephrologist-led and anticoagulation clinic-led management. *BMC Nephrol* 2018; **19**: 4 [PMID: 29310600 DOI: 10.1186/s12882-017-0809-x]

10 **McAlister FA**, Wiebe N, Hemmelgarn BR. Time in therapeutic range and stability over time for warfarin users in clinical practice: a retrospective cohort study using linked routinely collected health data in Alberta, Canada. *BMJ Open* 2018; **8**: e016980 [PMID: 29382672 DOI: 10.1136/bmjopen-2017-016980]

11 **Reiffel JA**. Time in the Therapeutic Range for Patients Taking Warfarin in Clinical Trials: Useful, but Also Misleading, Misused, and Overinterpreted. *Circulation* 2017; **135**: 1475-1477 [PMID: 28416519 DOI: 10.1161/CIRCULATIONAHA.116.026854]

12 **Macedo AF**, Bell J, McCarron C, Conroy R, Richardson J, Scowcroft A, Sunderland T, Rotheram N. Determinants of oral anticoagulation control in new warfarin patients: analysis using data from Clinical Practice Research Datalink. *Thromb Res* 2015; **136**: 250-260 [PMID: 26073321 DOI: 10.1016/j.thromres.2015.06.007]

13 **Vestergaard AS**, Skjøth F, Larsen TB, Ehlers LH. The importance of mean time in therapeutic range for complication rates in warfarin therapy of patients with atrial fibrillation: A systematic review and meta-regression analysis. *PLoS One* 2017; **12**: e0188482 [PMID: 29155884 DOI: 10.1371/journal.pone.0188482]

14 **Schmitt L**, Speckman J, Ansell J. Quality assessment of anticoagulation dose management: comparative evaluation of measures of time-in-therapeutic range. *J Thromb Thrombolysis* 2003; **15**: 213-216 [PMID: 14739631 DOI: 10.1023/B:THRO.0000011377.78585.63]

15 **Urbonas G**, Valius L, Šakalytė G, Petniūnas K, Petniūnienė I. The Quality of Anticoagulation Therapy among Warfarin-Treated Patients with Atrial Fibrillation in a Primary Health Care Setting. *Medicina (Kaunas)* 2019; **55** [PMID: 30650565 DOI: 10.3390/medicina55010015]

16 **Haas S**, Ten Cate H, Accetta G, Angchaisuksiri P, Bassand JP, Camm AJ, Corbalan R, Darius H, Fitzmaurice DA, Goldhaber SZ, Goto S, Jacobson B, Kayani G, Mantovani LG, Misselwitz F, Pieper K, Schellong SM, Stepinska J, Turpie AG, van Eickels M, Kakkar AK; GARFIELD-AF Investigators. Quality of Vitamin K Antagonist Control and 1-Year Outcomes in Patients with Atrial Fibrillation: A Global Perspective from the GARFIELD-AF Registry. *PLoS One* 2016; **11**: e0164076 [PMID: 27792741 DOI: 10.1371/journal.pone.0164076]

17 **Jones M**, McEwan P, Morgan CL, Peters JR, Goodfellow J, Currie CJ. Evaluation of the pattern of treatment, level of anticoagulation control, and outcome of treatment with warfarin in patients with non-valvar atrial fibrillation: a record linkage study in a large British population. *Heart* 2005; **91**: 472-477 [PMID: 15772203 DOI: 10.1136/hrt.2004.042465]

18 **Connolly SJ**, Pogue J, Eikelboom J, Flaker G, Commerford P, Franzosi MG, Healey JS, Yusuf S; ACTIVE W Investigators. Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. *Circulation* 2008; **118**: 2029-2037 [PMID: 18955670 DOI: 10.1161/CIRCULATIONAHA.107.750000]

19 **Peduzzi P,** Concato J, Kemper E, Holford TR, Feinstem AR. A simulation study of the number of events per variable in logistic regression analysis. *J Clin Epidemiol* 1996; **49**: 1373-1379 [DOI: 10.1016/S0895-4356(96)00236-3]

20 **Pokorney SD**, Simon DN, Thomas L, Fonarow GC, Kowey PR, Chang P, Singer DE, Ansell J, Blanco RG, Gersh B, Mahaffey KW, Hylek EM, Go AS, Piccini JP, Peterson ED; Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Investigators. Patients' time in therapeutic range on warfarin among US patients with atrial fibrillation: Results from ORBIT-AF registry. *Am Heart J* 2015; **170**: 141-148, 148.e1 [PMID: 26093875 DOI: 10.1016/j.ahj.2015.03.017]

21 Department of Statistics Malaysia Official Portal [Internet]. [cited 2020 Nov 4]. Available from: https://www.dosm.gov.my/v1/index.php?r=column/cthemeByCat&cat=430&bul\_id=aFYzVjJ3anNyQytHZGxzcUZxTG9Ydz09&menu\_id=L0pheU43NWJwRWVSZklWdzQ4TlhUUT09

22 **Björck F**, Kadhim H, Själander A. Predictors for INR-control in a well-managed warfarin treatment setting. *J Thromb Thrombolysis* 2019; **47**: 227-232 [PMID: 30411185 DOI: 10.1007/s11239-018-1765-4]

23 **Hong KS**, Kim YK, Bae HJ, Nam HS, Kwon SU, Bang OY, Cha JK, Yoon BW, Rha JH, Lee BC, Park JM, Park MS, Lee J, Choi JC, Kim DE, Lee KB, Park TH, Lee JS, Kim SE, Lee J. Quality of Anticoagulation with Warfarin in Korean Patients with Atrial Fibrillation and Prior Stroke: A Multicenter Retrospective Observational Study. *J Clin Neurol* 2017; **13**: 273-280 [PMID: 28748679 DOI: 10.3988/jcn.2017.13.3.273]

24 **Lane DA**, Lip GY. Use of the CHA(2)DS(2)-VASc and HAS-BLED scores to aid decision making for thromboprophylaxis in nonvalvular atrial fibrillation. *Circulation* 2012; **126**: 860-865 [PMID: 22891166 DOI: 10.1161/CIRCULATIONAHA.111.060061]

25 **Bernaitis N**, Ching CK, Chen L, Hon JS, Teo SC, Davey AK, Anoopkumar-Dukie S. The Sex, Age, Medical History, Treatment, Tobacco Use, Race Risk (SAMe TT2R2) Score Predicts Warfarin Control in a Singaporean Population. *J Stroke Cerebrovasc Dis* 2017; **26**: 64-69 [PMID: 27671097 DOI: 10.1016/j.jstrokecerebrovasdis.2016.08.030]

**Footnotes**

**Institutional review board statement:** Ethical approval for this study was obtained from the Medical Research and Ethics Committee (MREC), Ministry of Health Malaysia (NMRR-19-839-46462).

**Informed consent statement:** Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment. Permission to use the patient data from this facility has been obtained from the Head of Department of Cardiology, Hospital Serdang.

**Conflict-of-interest statement:** The authors have no financial relationships to disclose.

**Data sharing statement:** No additional data are available.

**Open-Access:** This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Peer-review started:** March 10, 2021

**First decision:** May 6, 2021

**Article in press:**

**Specialty type:** Cardiac and cardiovascular systems

**Country/Territory of origin:** Malaysia

**Peer-review report’s scientific quality classification**

Grade A (Excellent): 0

Grade B (Very good): 0


Grade C (Good): 0

Grade D (Fair): D


Grade E (Poor): 0

**P-Reviewer:** luo W **S-Editor:** Ma YJ **L-Editor:** Filipodia **P-Editor:**


**Figure Legends**



**Figure 1 Flow diagram describing the selection of data for the analysis reported.** AF: atrial fibrillation; INR: International normalized ratio; MTAC: Medication Therapeutic Adherence Clinic.



**Figure 2 Mean percentage of the time in therapeutic range among atrial fibrillation patients.** TTR: time in therapeutic range.



**Figure 3 HAS-BLED score *vs* median time in therapeutic range (%).** TTR: Time in therapeutic range.

**Table 1 Baseline characteristics**

|  |  |  |  |
| --- | --- | --- | --- |
| **Baseline characteristic** | **All patients, *n =* 420** | **TTR < 60%, *n =* 178** | **TTR ≥ 60%, *n =* 242** |
| Age, yr |  |  |  |
| mean ± SD | 65.7 ± 10.9 | 65.7 ± 10.8 | 65.7± 10.9 |
| Median (IQR) | 67 (15) | 66 (14) | 67 (15) |
| Male | 227(54.0) | 99 (55.6) | 128 (52.9) |
| Female | 193 (46.0) | 79 (44.4) | 114 (47.1) |
| Ethnicity |  |  |  |
| Malay | 210 (50.0) | 96 (53.9) | 114 (47.1) |
| Chinese | 179 (42.6) | 64 (36.0) | 115 (47.5) |
| Indian | 26 (6.2) | 16 (9.0) | 10 (4.1) |
| Others | 5 (1.2) | 2 (1.1) | 3 (1.2) |
| Comorbidities |  |  |  |
| Diabetes mellitus | 170 (40.5) | 85 (47.8) | 85 (35.1) |
| Hypertension | 291 (69.3) | 128 (71.9) | 163 (67.4) |
| Ischemic heart disease | 90 (21.4) | 48 (27.0) | 42 (17.4) |
| Peripheral vascular disease | 8 (1.9) | 2 (1.1) | 6 (2.5) |
| Stroke/transient ischemic attack | 49 (11.7) | 20 (11.2) | 29 (12.0) |
| Deep vein thrombosis/pulmonary embolism | 2 (0.5) | 1 (0.6) | 1 (0.4) |
| Heart failure | 27 (6.4) | 12 (6.7) | 15 (6.2) |
| Chronic obstructive pulmonary disease/asthma | 22 (5.2) | 8 (4.5) | 14 (5.8) |
| Chronic kidney disease | 49 (11.7) | 28 (15.7) | 21 (8.7) |
| Dyslipidaemia | 125 (29.8) | 47 (26.4) | 78 (32.2) |
| Chronic rheumatic heart disease | 17 (4.0) | 10 (5.6) | 7 (2.9) |
| Liver disease | 0 (0.0) | 0 (0.0) | 0 (0.0) |
| CHA2DS2-VASc score |  |  |  |
| Mean ± SD  Median (IQR) | 2.6 ± 1.4  3 (1.0) | -  3 (2) | -  2(1) |
| Score 0-1 | 91 (21.7) | 34 (19.1) | 57 (23.6) |
| Score 2-4 | 297 (70.7) | 125 (70.2) | 172 (71.1) |
| Score ≥ 5 | 32 (7.6) | 19 (10.7) | 13 (5.4) |
| HAS-BLED score |  |  |  |
| Median (IQR) | 2 (2.0) | 3 (1.0) | 2 (2.0) |
| Low bleeding risk (score ≤ 2) | 257 (61.2) | 83 (46.6) | 174 (71.9) |
| High bleeding risk (score ≥ 3) | 163 (38.8) | 95 (53.4) | 68 (28.1) |

All values are reported as *n* (%) unless otherwise noted. IQR: interquartile range; TTR: Time in therapeutic range; SD Standard deviation.

**Table 2 Time in the therapeutic range of the study population**

|  |  |  |  |
| --- | --- | --- | --- |
| **Variables** | **All patients,**  ***n =* 420** | **TTR < 60%, *n =* 178** | **TTR ≥ 60%, *n =* 242** |
| TTR |  |  |  |
| mean ± SD | 60.6 ± 20.6 | 41.1 ± 14.7 | 75.0 ± 9.6 |
| Median (IQR) | 64 (27) | 44 (22) | 74 (14) |
| Good (≥ 60%) | 242 (57.6) | - | - |
| Poor (< 60%) | 178 (42.4) | - | - |

SD: Standard deviation; TTR: Time in therapeutic range.

**Table 3 Univariate and multivariate logistic regression analysis for predictors of poor time in therapeutic range < 60% among atrial fibrillation patients**

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Baseline characteristic** | **Univariate** | | | **Multivariate** | | | | | | | |
| **Model 1**1 | | | | | **Model 2**2 | | |
| **OR** | **95%CI** | ***p*** | **aOR** | **95%CI** | | ***p*** | | **aOR** | **95%CI** | ***p*** |
| Age | 1.0 | 0.9-1.0 | 0.976 |  | | | | |  |  | |
| Ethnicity |  |  |  |  | | | | |  |  | |
| Malay | 1.0 | reference | - |  | | | | |  |  | |
| Chinese | 1.3 | 0.2-7.7 | 0.800 |  | | | | |  |  | |
| Indian | 0.8 | 0.1-5.1 | 0.845 |  | | | | |  |  | |
| Others | 2.4 | 0.3-16.9 | 0.380 |  | | | | |  |  | |
| Gender |  |  |  |  | | | | |  |  | |
| Male | 1.0 | reference | - |  | | | | |  |  | |
| Female | 0.9 | 0.6-1.3 | 0.580 |  | | | | |  |  | |
| Comorbidities |  |  |  |  | | | | |  |  | |
| Diabetes mellitus | 1.7 | 1.1-2.5 | 0.009 | 1.3 | | 0.8-1.9 | | 0.240 |  |  | |
| Hypertension | 1.2 | 0.8-1.9 | 0.318 |  | | | | |  |  | |
| Ischemic heart disease | 1.8 | 1.1-2.8 | 0.018 | 1.3 | | 0.8-2.1 | | 0.317 |  |  | |
| Peripheral vascular disease | 0.4 | 0.1-2.2 | 0.328 |  | | | | |  |  | |
| Stroke/transient ischemic attack | 0.9 | 0.5-1.7 | 0.814 |  | | | | |  |  | |
| Deep vein Thrombosis/pulmonary  embolism | 1.4 | 0.1-21.9 | 0.828 |  | | | | |  |  | |
| Heart failure | 1.1 | 0.5-2.4 | 0.823 |  | | | | | 1.0 | 0.5-2.4 | 0.913 |
| Chronic obstructive pulmonary  disease/asthma | 0.8 | 0.3-1.9 | 0.558 |  | | | | |  |  | |
| Chronic kidney disease | 1.9 | 1.1-3.6 | 0.028 | 1.2 | | 0.6-2.3 | | 0.585 | 1.2 | 0.7-2.4 | 0.514 |
| Dyslipidaemia | 0.7 | 0.5-1.2 | 0.197 |  | | | | |  |  | |
| Chronic rheumatic heart disease | 1.9 | 0.8-5.4 | 0.169 |  | | | | |  |  | |
| CHA2DS2-VASc score | 1.4 | 0.9-2.1 | 0.060 |  | | | | | 0.9 | 0.6-1.4 | 0.629 |
| HAS-BLED Score  Low bleeding risk (score ≤ 2) | 1.0 | reference | - |  | |  | |  |  |  |  |
| High bleeding risk (score ≥ 3) | 2.9 | 1.9-4.4 | < 0.001 | 2.5 | | 1.6-3.9 | | < 0.001 | 2.9 | 1.8-4.7 | < 0.001 |
| 1Model 1, adjusted to significant variables of the study populations. 2Model 2, adjusted to heart failure, chronic kidney disease, CHA2DS2-VASc score and HAS-BLED score. aOR: adjusted odds ratio; CI: Confidence interval; TTR: Time in therapeutic range. | | | | | | | | | | | |